# A Study of Mirikizumab (LY3074828) in Pediatric Participants With Crohn's Disease

> **NCT05509777** · PHASE3 · RECRUITING · sponsor: **Eli Lilly and Company** · enrollment: 90 (estimated)

## Conditions studied

- Crohn's Disease

## Interventions

- **DRUG:** Mirikizumab

## Key facts

- **NCT ID:** NCT05509777
- **Lead sponsor:** Eli Lilly and Company
- **Sponsor class:** INDUSTRY
- **Phase:** PHASE3
- **Study type:** INTERVENTIONAL
- **Status:** RECRUITING
- **Start date:** 2024-03-13
- **Primary completion:** 2027-12
- **Final completion:** 2028-04
- **Target enrollment:** 90 (ESTIMATED)
- **Last updated:** 2026-03-27


## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT05509777

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT05509777, "A Study of Mirikizumab (LY3074828) in Pediatric Participants With Crohn's Disease". Retrieved via AI Analytics 2026-09-04 from https://api.ai-analytics.org/clinical/NCT05509777. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*